Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years

Lupus

Volumn 26, Issue 11, 2017, Pages 1197-1204

  Taraborelli, M ^a   Cavazzana, I ^a   Martinazzi, N ^b   Lazzaroni, M Grazia ^b   Fredi, M ^a   Andreoli, L ^b   Franceschini, F ^a   Tincani, A ^a  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

antiphospholipid antibodies; damage; disease activity; neuropsychiatric damage; Systemic lupus erythematosus

Indexed keywords

CARDIOLIPIN ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; PHOSPHOLIPID ANTIBODY; SM ANTIBODY; BIOLOGICAL MARKER;

ADULT; ALOPECIA; ARTICLE; BRAIN ISCHEMIA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE ORGAN FAILURE; PREVALENCE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; RISK FACTOR; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CHI SQUARE DISTRIBUTION; DISEASE EXACERBATION; ITALY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR; YOUNG ADULT;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; BIOMARKERS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; LINEAR MODELS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 85028994337     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203317693096     Document Type: Article

References (39)

1. Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 2152-2158.
2. Urowitz MB, Bookman AA, Koehfler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
3. Sutton EJ, Davidson JE, Bruce IN,. The Systemic Lupus International Collaborating Clinics (SLICC) Damage Index: A systemic literature review. Semin Arthritis Rheum 2013; 43: 352-361.
4. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
5. Fredi M, Cavazzana I, Taraborelli M, et al. Prolonged assumption of HCQ is associated with longer survival in SLE. Ann Rheum Dis 2014; 73: 77-77.
6. Ruiz-Irastorza G, Egurbide MV, Ugalde J, et al. High Impact of Antiphospholipid Syndrome on Irreversible Organ Damage and Survival of Patients with Systemic Lupus Erythematosus. Arch Intern Med 2004; 164: 77-82.
7. Taraborelli M, Leuenberger L, Lazzaroni MG, et al. The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. Lupus 2016; 25: 1365-1368.
8. Petri M, Purvey S, Fang H, Magder LS,. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012; 64: 4021-4028.
9. Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, et al. Antiphospholipid antibodies predict damage in patients with systemic lupus erythematosus. Lupus 2004; 13: 900-905.
10. Conti F, Ceccarelli F, Perricone C, et al. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. Lupus 2016; 25: 719-726.
11. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
12. Gladman DD, Ibanez D, Urowitz MB,. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
13. Bernstein RM, Bunn CC, Hughes GRV,. Identification of antibodies to acidic antigens by counterimmunoelectrophoresis. Ann Rheum Dis 1982; 41: 554-555.
14. Harris EN,. The Second International anti-cardiolipin standardization workshop. The Kingston anti-phospholipid antibody study (KAPS) group. Ann J Clin Pathol 1990; 94: 476-484.
15. Balestrieri G, Tincani A, Spatola L, et al. Anti-ß2 glycoprotein I: a marker of antiphospholipid syndrome? Lupus 1995; 4: 122-130.
16. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS,. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-1959.
17. Chambers SA, Allen E, Rahman A, Isenberg D,. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009; 48: 673-675.
18. Estevez del Toro M, Chico Capote A, Hechavarria R, et al. Damage in cuban patients with systemic lupus erythematosus. Relation with disease features. Rheumatol Clin 2010; 6: 11-15.
19. Becker-Merok A, Nossent HC,. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006; 33: 1570-1577.
20. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19: 949-956.
21. Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med 2015; 2: e000066-e000066.
22. Bruce IN, O'Kneeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2015; 74: 1706-1713.
23. Stoll T, Sutcliff N, Mach J, Klaghofer R, Isenberg DA,. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus- a 5-yr prospective study. Rheumatology (Oxford) 2004; 43: 1039-1044.
24. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA,. Lupus disease activity and risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford) 2012; 51: 491-498.
25. Nossent JC,. SLICC/ACR damage Index in Afro-Carribean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol 1998; 25: 654-659.
26. Santos MJ, Vinagre F, Nero P, et al. Predictors of damage progression in Portuguese patients with Systemic Lupus Erythematosus. Cont Challages Rheumatol. Ann NY Acad Sci 2009; 1173: 822-828.
27. Stoll T, Seifert B, Isenberg DA,. SLICC/ACR Damage index is valid, and renal ad pulmonary orgen scores are predictors of severe outcome in patients with systemic lupus erythematosus. Lupus 2004; 13: 900-905.
28. Alarcon GS, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) 2004; 43: 202-205.
29. Zonana-Nacach A, Camargo-Coronel A, Yanez P, et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 1998; 7: 119-123.
30. Sung YK, Hur NW, Sinskey JL, et al. Assessment of damage in Korean patients with systemic lupus erythematosus. J Rheumatol 2007; 34: 987-991.
31. Swaak AJ, Groenwold J, Brosveld W,. Predictive value of complement profile and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 359-366.
32. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG,. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 1990; 33: 634-643.
33. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C,. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 2003; 42: 276-279.
34. Govoni M, Bombardieri S, Bortoluzzi A, et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology (Oxford) 2012; 51: 157-168.
35. Muscal E, Brey RL,. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus 2010; 19: 406-411.
36. Bonakdar ZS, Mohtashmam N, Karimifar M,. Evaluation of damage index and its association with risk factor in patients with systemic lupus erythematosus. J Res Med Sci 2011; 16: S427-S432.
37. Zonana-Nacach A, Barr SC, Magder LS, Petri M,. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-1808.
38. Alderaan K, Sekiki V, Magder LS, Petri M,. Risk factors for cataracts in systemic lupus erythematosus (SLE). Rheumatol Int 2015; 35: 701-708.
39. Petri M,. Musculo-skeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res 1995; 8: 137-145.